FrancophonIA/ELRC3.0 huggingface dataset:
English: There was no evidence of maternal or foetal toxicity, and no effects on pregnancy, maternal behaviour, female fertility, or postnatal development in a study in which female rabbits received Bexsero at approximately 10 times the human dose equivalent based on body weights.
Slovenian: V študiji na kunčjih samicah, ki so prejele cepivo Bexsero v odmerku, ki je približno 10-krat večji od človeškega ekvivalenta na osnovi telesne mase, niso ugotovili dokazov toksičnosti za mater ali plod oz. učinkov na brejost, obnašanje matere, plodnost samic ali postnatalni razvoj.
English: NAME OF THE MEDICINAL PRODUCT Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed)
Slovenian: Navodilo za uporabo Bexsero suspenzija za injiciranje v napolnjeni injekcijski brizgi cepivo proti meningokokom skupine B (rekombinantno, komponentno, adsorbirano)
English: General disorders and administration site conditions Very common: injection site pain (including severe injection site pain defined as unable to perform normal daily activity), injection site swelling, injection site induration, injection site erythema, malaise
Slovenian: Zelo pogosti: bolečina na mestu injiciranja (vključno s hudo bolečino na mestu injiciranja, ki je opredeljena kot nezmožnost opravljanja običajnih dnevnih dejavnosti), oteklina na mestu injiciranja, zatrdlina na mestu injiciranja, eritem na mestu injiciranja, slabo počutje Neznana pogostnost: zvišana telesna temperatura, reakcije na mestu injiciranja (vključno z obsežno oteklino cepljenega uda, mehurji na mestu injiciranja ali okoli njega in nodulom na mestu injiciranja,
English: Ask your doctor for advice whether it is beneficial for you to receive Bexsero.
Slovenian: Posvetujte se s svojim zdravnikom ali medicinsko sestro, ali je cepljenje s cepivom Bexsero koristno za vas.
English: % seropositive (95% CI) hSBA GMT (95% CI) 18-23 months after 2nd dose
Slovenian: % seropozitivnih (95 % IZ) hSBA GST (95 % IZ) 18-23 mesecev po 2. odmerku
English: Seroresponse rates and percentages of subjects with at least a 4-fold increase in hSBA titer from baseline to one month after the second dose of Bexsero are summarised in Table 8.
Slovenian: V preglednici 8 so povzete stopnje serološkega odziva in odstotki preiskovancev, ki jim je titer hSBA od izhodišča do enega meseca po drugem odmerku cepiva Bexsero porasel za vsaj 4-krat.
English: Higher rates of antipyretic use were also reported for infants vaccinated with Bexsero and routine vaccines.
Slovenian: Pri dojenčkih, cepljenih s cepivom Bexsero in rutinskimi cepivi, je bila ugotovljena tudi večja pogostnost uporabe antipiretikov.
English: % seropositive* (95% CI) hSBA GMT** (95% CI) 18-23 months after 2nd dose
Slovenian: % seropozitivnih* (95 % IZ) hSBA GST** (95 % IZ) 18−23 mesecev po 2. odmerku
English: Recombinant Neisseria meningitidis group B fHbp fusion protein 1, 2, 3
Slovenian: 50 mikrogramov rekombinantna fuzijska beljakovina fHbp iz Neisseria meningitidis skupine B 1, 2, 3
English: Persistence of the immune response one year after the booster dose is also presented in Table 3.
Slovenian: V preglednici 3 so prikazani tudi podatki o perzistenci imunskega odziva eno leto po poživitvenem odmerku.
English: Contents of the pack and other information
Slovenian: Shranjevanje cepiva Bexsero Vsebina pakiranja in dodatne informacije
English: % seropositive (95% CI) hSBA GMT (95% CI) 12 months after 2nd dose
Slovenian: % seropozitivnih (95 % IZ) hSBA GST (95 % IZ) 12 mesecev po 2. odmerku
English: % seropositive* (95% CI) hSBA GMT** (95% CI) 12 months after 2nd dose
Slovenian: % seropozitivnih* (95 % IZ) hSBA GST** (95 % IZ) 12 mesecev po 2. odmerku
English: Adolescents (from 11 years of age) and adults
Slovenian: Mladostniki (stari 11 let in več) in odrasli
English: Ask your doctor or nurse how to throw away medicines you no longer use.
Slovenian: O načinu odstranjevanja cepiva, ki ga ne uporabljate več, se posvetujte z zdravnikom ali medicinsko sestro.
English: - The first injection should be given no earlier than 2 months of age if three initial doses are given; the interval between injections should be at least 1 month.
Slovenian: - Prve injekcije ne smete dati pred 2 mesecema starosti, če so dani trije osnovni odmerki;
English: GlaxoSmithKline GmbH & Co. KG Tel: +49 (0)89 36044 8701 de.impfservice@gsk.com
Slovenian: KG Tel: +49 (0)89 36044 8701 de.impfservice@gsk.com
English: 12 months after booster % seropositive (95% CI) hSBA GMT (95% CI)
Slovenian: 12 mesecev po poživitvenem odmerku % seropozitivnih (95 % IZ) hSBA GST (95 % IZ)
English: Two doses each of 0.5 ml
Slovenian: mesecev dva odmerka po 0,5 ml vsaj 2 meseca dojenčki,
English: Age at first dose Primary Immunisation
Slovenian: Preglednica 1: Povzetek odmerjanja Starost ob prvem odmerku
English: Bexsero is not expected to provide protection against all circulating meningococcal group B strains (see section 5.1).
Slovenian: Cepivo Bexsero ne zagotovi nujno zaščite pred vsemi krožečimi sevi meningokokov skupine B
English: Very common (these may affect more than 1 in 10 people) - fever (≥38ºC) - loss of appetite - tenderness at the injection site (including severe injection site tenderness resulting in crying when injected limb is moved) - painful joints - skin rash (children aged 12 to 23 months) (uncommon after booster) - sleepiness - feeling irritable - unusual crying - vomiting (uncommon after booster) - diarrhoea - headache
Slovenian: - občutljivost na mestu injiciranja (vključno s hudo občutljivostjo mesta injiciranja, ki privede do joka, če se premakne ud, kjer je bilo injicirano cepivo) - boleči sklepi - kožni izpuščaj (otroci, stari od 12 do 23 mesecev) (po poživitvenem odmerku je ta učinek občasen)
English: % seropositive* (95% CI) hSBA GMT** (95% CI)
Slovenian: % seropozitivnih* (95 % IZ) hSBA GST** (95 % IZ)
English: Bexsero is a Meningococcal group B Vaccine.
Slovenian: Kaj je cepivo BEXSERO in za kaj ga uporabljamo Cepivo Bexsero je cepivo proti meningokokom skupine B.
English: Immunogenicity results at one month after three doses of Bexsero administered at 2, 3, 4 and 2, 4, 6 months of age are summarised in Table 2.
Slovenian: Zaporedje cepljenja s tremi odmerki, ki mu sledi poživitveni odmerek V preglednici 2 so povzeti rezultati imunogenosti en mesec po treh odmerkih cepiva Bexsero, danih v starosti 2, 3, 4 oz. 2, 4, 6 mesecev.
English: 1 month after booster % seropositive (95% CI) hSBA GMT (95% CI)
Slovenian: 1 mesec po poživitvenem odmerku % seropozitivnih (95 % IZ) hSBA GST (95 % IZ)
English: Uncommon (these may affect up to 1 in 100 people) - high fever (≥40°C) - seizures (including febrile seizures) - dry skin - paleness (rare after booster)
Slovenian: - kožni izpuščaj (dojenčki in otroci, stari od 2 do 10 let) Občasni (pojavijo se lahko pri največ 1 od 100 cepljenih oseb) - zelo zvišana telesna temperatura (≥ 40 °C) - krči (vključno z vročinskimi krči)
English: Recombinant Neisseria meningitidis group B NHBA fusion protein 1, 2, 3
Slovenian: rekombinantna fuzijska beljakovina NHBA iz Neisseria meningitidis skupine B 1, 2, 3 50 mikrogramov rekombinantna beljakovina NadA iz Neisseria meningitidis skupine B 1, 2, 3
English: Adolescents received two doses of Bexsero with one, two or six month intervals between doses; these data are summarised in Tables 7 and 8.
Slovenian: Mladostniki so prejeli dva odmerka cepiva Bexsero z eno-, dvo- ali šestmesečnim presledkom med odmerkoma.
English: Recombinant Neisseria meningitidis group B NadA protein 1, 2, 3
Slovenian: 50 mikrogramov rekombinantna beljakovina NadA iz Neisseria meningitidis skupine B 1, 2, 3
English: 6 to 11 months of age
Slovenian: starih 13-15 mesecev.
English: Serum bactericidal antibody responses at 1 month following the second dose of Bexsero given to children 2-10 years of age following a 0, 1-month schedule
Slovenian: Preglednica 6: Odzivi serumskih baktericidnih protiteles 1 mesec po cepljenju otrok, starih 2-10 let z drugim odmerkom cepiva Bexsero po shemi 0, 1 mesec
English: Data on bactericidal antibody persistence at 8 months after Bexsero vaccination at 2, 3 and 4 months of age, and at 6 months after Bexsero vaccination at 2, 4 and 6 months of age (pre-booster time point) and booster data after a fourth dose of Bexsero administered at 12 months of age are summarised in Table 3.
Slovenian: V preglednici 3 so povzeti podatki o perzistenci protiteles 8 mesecev po cepljenju s cepivom Bexsero v starosti 2, 3 in 4 mesecev in 6 mesecev po cepljenju s cepivom Bexsero v starosti 2, 4 in 6 mesecev
English: % seropositive (95% CI) hSBA GMT (95% CI)
Slovenian: % seropozitivnih (95 % IZ) hSBA GST (95 % IZ)
English: Use with other vaccines
Slovenian: UPORABO ZDRAVILA
English: Water for injections
Slovenian: NAPOLNJENA INJEKCIJSKA BRIZGA
English: Recombinant Neisseria meningitidis group B NHBA fusion/NadA/fHbp fusion proteins
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Odmerek (0,5 ml) vsebuje: rekombinantne fuzijske NHBA/NadA/fuzijske fHbp beljakovine iz Neisseria meningitidis skupine B
English: STATEMENT OF ACTIVE SUBSTANCE(S) 0.5 ml dose contains:
Slovenian: suspenzija za injiciranje (0,5 ml)
English: Gastrointestinal disorders Very common: nausea
Slovenian: Bolezni prebavil Zelo pogosti: navzea
English: Serum bactericidal antibody responses at 1 month following the second dose of Bexsero given to children 2-10 years of age following a 0, 2-month schedule
Slovenian: Preglednica 5: Odziv serumskih baktericidnih protiteles 1 mesec po cepljenju otrok starih 210 let z drugim odmerkom cepiva Bexsero po shemi 0, 2
English: Gastrointestinal disorders Very common: diarrhoea, vomiting (uncommon after booster)
Slovenian: Zelo pogosti: driska, bruhanje (po poživitvenem odmerku občasno)
English: pre-booster % seropositive (95% CI) hSBA GMT (95% CI)
Slovenian: pred poživitvenim odmerkom % seropozitivnih (95 % IZ) hSBA GST (95 % IZ)
English: 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea.eu.int http://www.emea.eu.int©EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
Slovenian: 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail@emea.europa.eu http://www.emea.europa.eu©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
English: International Non-proprietary Name (INN): tegaserod
Slovenian: Mednarodno nelastniško ime (INN): tegaserod
English: Following request from the applicant, the CHMP re-examined the opinion and confirmed its previous view on 23 March 2006.
Slovenian: CHMP je po zahtevi vlagatelja ponovno pregledal mnenje in dne 23. marca 2006 potrdil prejšnje mnenje.
English: The company who applied is Novartis Europharm Limited.
Slovenian: Vlagatelj je podjetje Novartis Europharm Limited.
English: Treatments were double blinded (neither the patients nor the doctors knew which treatment had been given until the end of the study).
Slovenian: Postopka zdravljenja sta bila dvojno slepa (niti bolniki niti zdravniki do konca raziskave niso vedeli, katero zdravilo so bolniki dobili).
English: These effects are expected to relieve the symptoms described.
Slovenian: Ti učinki naj bi lajšali opisane simptome.
English: European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use
Slovenian: European Medicines Agency
English: On 15 December 2005 the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Zelnorm 6 mg tablets.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je v negativnem mnenju z dne 15. decembra 2005 priporočil zavrnitev dovoljenja za promet z zdravilom Zelnorm 6 mg tablete.
English: If you are in a Zelnorm clinical trial for irritable bowel syndrome or any other indication under development and need more information about your treatment, contact the doctor who is giving it to you.
Slovenian: Če ste vključeni v klinično preizkušanje zdravila Zelnorm za sindrom iritabilnega kolona ali katerokoli drugo indikacijo v razvoju ter potrebujete več podatkov o zdravljenju, se obrnite na zdravnika, ki vam je predpisal zdravljenje.
English: The main study in humans was done in 2660 women aged 18 to 65 years, and with symptoms of irritable bowel syndrome with constipation.
Slovenian: Glavna raziskava pri ljudeh je bila opravljena pri 2660 ženskah, starih od 18 do 65 let, s simptomi sindroma iritabilnega kolona z zaprtjem.
English: These symptoms include pain or discomfort in the stomach or abdomen and a feeling of bloating.
Slovenian: Ti simptomi vključujejo bolečine ali nelagodje v želodcu ali trebuhu in občutek napihnjenosti.
English: It contains 6 mg of the active ingredient tegaserod.
Slovenian: Vsebujejo 6 mg zdravilne učinkovine tegaserod.
English: The effects of Zelnorm were first tested in experimental models before being studied in humans.
Slovenian: Učinki zdravila Zelnorm so bili najprej preizkušeni s pomočjo izkustvenih modelov, nato pa so jih raziskali pri ljudeh.
English: The CHMP was concerned that the results of the study would not translate into real benefit to the patient treated to relieve the symptoms of this disorder in standard health care setting.
Slovenian: CHMP je skrbelo, da rezultati raziskave ne odražajo pravih koristnih učinkov za bolnika, ki bi se zdravil za lajšanje simptomov te bolezni v običajnem zdravstvenem okolju.
English: It activates receptors in the body, known as 5-hydroxytryptamine (5HT) type 4 receptors.
Slovenian: Aktivira receptorje v telesu, ki jim pravimo receptorji 5-hidroksitriptamina (5HT) tipa 4.
English: The CHMP was of the opinion that Zelnorm's benefits are not greater than its risks.
Slovenian: CHMP meni, da koristni učinki zdravila Zelnorm niso večji od tveganja.
English: What are the consequences of the refusal for patients undergoing clinical trials with Zelnorm?
Slovenian: Kakšne so posledice zavrnitve za bolnike, ki sodelujejo v kliničnih preizkušanjih z zdravilom Zelnorm?
English: Which documentation has been presented by the Company to support the application to the CHMP?
Slovenian: Katero dokumentacijo je podjetje predložilo CHMP za podporo vlogi?
English: It causes abnormal bowel function and makes the intestines more sensitive to normal stimulation, resulting in the above-mentioned symptoms.
Slovenian: Povzroča nenormalno delovanje kolona, črevesje postane občutljivejše za normalno stimulacijo, kar povzroči zgoraj omenjene simptome.
English: QUESTIONS AND ANSWERS ON RECOMMENDATION FOR REFUSAL OF MARKETING APPLICATION for ZELNORM
Slovenian: VPRAŠANJA IN ODGOVORI GLEDE PRIPOROČILA ZA ZAVRNITEV VLOGE ZA DOVOLJENJE ZA PROMET za zdravilo ZELNORM
English: Tegaserod, the active ingredient in Zelnorm, is a receptor agonist.
Slovenian: Tegaserod, zdravilna učinkovina v zdravilu Zelnorm, je agonist receptorja.
English: They also potentially reduce the sensitivity of the bowel.
Slovenian: Ti receptorji naj bi potencialno zmanjšali občutljivost črevesja.
English: When these receptors are activated in the bowels, peristalsis that moves food along the bowels is stimulated.
Slovenian: Ob aktivaciji teh receptorjev v črevesju pride do stimulacije peristaltike, ki pomika hrano po črevesju.
English: The study compared Zelnorm 6 mg to placebo (a dummy treatment).
Slovenian: Raziskava je primerjala zdravilo Zelnorm 6 mg s placebom (zdravilo brez zdravilne učinkovine).
English: The study looked at the effectiveness of Zelnorm to relieve the overall symptoms of the disease and discomfort or pain in the stomach or abdomen.
Slovenian: V raziskavi so preverjali učinkovitost zdravila Zelnorm pri lajšanju vseh simptomov bolezni ter nelagodja ali bolečin v želodcu ali trebuhu.
English: Which were the major concerns, which lead to the refusal of the marketing authorisation by the CHMP?
Slovenian: Kateri so bili glavni zadržki zaradi katerih je CHMP zavrnil dovoljenje za promet?
English: Zelnorm is approved outside the European Union for the treatment of irritable bowel syndrome and chronic constipation.
Slovenian: Zdravilo Zelnorm je odobreno izven Evropske Unije za zdravljenje sindroma iritabilnega kolona in kroničnega zaprtja.
English: What is Zelnorm?
Slovenian: Kaj je zdravilo Zelnorm?
English: EMEA/CHMP/109088/2006
Slovenian: EMEA/H/C/621
English: Hence, the CHMP recommended that Zelnorm be refused marketing authorisation.
Slovenian: Zato je CHMP priporočil zavrnitev dovoljenja za promet z zdravilom Zelnorm.
English: What was Zelnorm expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Zelnorm uporabljalo?
English: No consequences for patients undergoing clinical trials have been identified by the CHMP.
Slovenian: CHMP ni ugotovil posledic za bolnike, ki sodelujejo v kliničnih preizkušanjih.
English: Zelnorm is a tablet to be swallowed.
Slovenian: Zdravilo Zelnorm so tablete, ki se pogoltnejo.
English: How is Zelnorm expected to work?
Slovenian: Kako naj bi zdravilo Zelnorm delovalo?
English: Zelnorm was expected to be used to relieve the symptoms of irritable bowel syndrome with constipation in women.
Slovenian: Zdravilo Zelnorm naj bi se uporabljalo za lajšanje simptomov sindroma iritabilnega kolona z zaprtjem pri ženskah.
English: Irritable bowel syndrome with constipation is a common disorder of the lower digestive system.
Slovenian: Sindrom iritabilnega kolona z zaprtjem je pogosta bolezen spodnjih prebavnih poti.
English: Zelnorm aims to relieve the symptoms of irritable bowel syndrome with constipation in women.
Slovenian: Zdravilo Zelnorm je namenjeno lajšanju simptomov sindroma iritabilnega kolona z zaprtjem pri ženskah.
English: EMEA/CHMP/109088/2006 0.8, CURRENT ©EMEA 2006
Slovenian: ©EMEA 2007
English: 24 months.
Slovenian: 24 mesecev.
English: This could be dangerous to yourself and others.
Slovenian: To je lahko nevarno za vas in za druge.
English: • You are elderly.
Slovenian: • če ste starejši,
English: Ask your doctor whether you can drive if:
Slovenian: Zdravnika vprašajte, ali lahko vozite:
English: • Your medicine has become less effective - for example because it was not stored properly.
Slovenian: • Vaše zdravilo je postalo manj učinkovito - na primer ker ni bilo pravilno shranjeno.
English: This must always be treated by a doctor, normally in a hospital.
Slovenian: To stanje mora vedno zdraviti zdravnik, praviloma v bolnišnici.
English: Be especially aware of the following:
Slovenian: Posebej se morate zavedati naslednjega:
English: • How much Suliqua you need each day and at what time.
Slovenian: • Koliko zdravila Suliqua potrebujete na dan in ob katerem času.
English: You also need to be careful when you stop taking a medicine.
Slovenian: Previdni morate biti tudi, ko nehate jemati kakšno zdravilo.
English: • You drink alcohol - especially when you have not eaten much.
Slovenian: • Pili ste alkohol - zlasti če niste dovolj jedli.
English: • You may need to repeat this step up to 3 times before seeing medicine.
Slovenian: • Ta korak boste morda morali ponoviti do 3-krat, preden se bo pojavilo zdravilo.
English: ATC Code: A10AE54.
Slovenian: Oznaka ATC : A10AE54.
English: • When you may need a higher or lower dose.
Slovenian: • Kdaj boste morda potrebovali večji ali manjši odmerek.
English: • What you should do in an emergency if you feel unwell or become ill.
Slovenian: • Kaj morate storiti v nujnem primeru, če se ne počutite dobro ali če zbolite.
English: Be familiar with your warning signs.
Slovenian: [15,0 do 26,7]
English: • Any health risks in the countries you will visit.
Slovenian: • O morebitnih zdravstvenih tveganjih v državah, ki jih boste obiskali.
English: • Information so that others know you have diabetes.
Slovenian: • Ustrezne informacije, tako da drugi vedo, da imate sladkorno bolezen.
English: Specific recommendations regarding intake of such medicinal products are given in section 4.5.
Slovenian: Specifična priporočila za jemanje takšnih zdravil so navedena v poglavju 4.5.
English: A. Choose a place to inject as shown in the picture above.
Slovenian: A. Izberite mesto za injiciranje, kot prikazuje slika zgoraj.
English: The median duration of study follow-up was 6.2 years.
Slovenian: Mediano spremljanje v študiji je trajalo 6,2 leta.
English: If you use insulin, you should always carry the following things with you:
Slovenian: Če uporabljate insulin, morate vedno imeti pri sebi:
English: Talk to your doctor before travelling.
Slovenian: Pred potovanjem se posvetujte z zdravnikom.
English: This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).
Slovenian: To je lahko nevarno v okoliščinah, v katerih sta ti zmožnosti posebej pomembni (npr. pri vožnji avtomobila ali upravljanju strojev).
English: This difference is not considered clinically relevant.
Slovenian: Ta razlika ne velja za klinično pomembno.
English: Elderly (≥65 years old)
Slovenian: Starejši bolniki (stari ≥ 65 let)
English: The first signs may be in your body generally.
Slovenian: Prvi znaki so lahko splošni telesni znaki.
English: For single patient use only.
Slovenian: Le za uporabo enega samega bolnika.
English: Any other OADs were discontinued.
Slovenian: Vse druge POAD so ukinili.
English: • How to correctly store your medicine while travelling.
Slovenian: • Kako pravilno shranjevati zdravilo med potovanjem.
English: These signs often develop before the signs of a low sugar level in the brain.
Slovenian: Ti znaki se pogosto pojavijo pred znaki nizkega krvnega sladkorja v možganih.
English: • Each pen contains more than 1 dose.
Slovenian: • Vsak peresnik vsebuje več kot 1 odmerek.
English: • During the switch to this type of combination medicine and in the weeks after the switch you should measure your blood sugar levels more frequently.
Slovenian: • Med prehodom na to vrsto kombiniranega zdravila in v tednih po prehodu si morate krvni sladkor meriti pogosteje.
English: DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION Date of first authorisation: 11 January 2017
Slovenian: Datum prve odobritve: 11. januar 2017
English: • If you have poor eyesight, please see section 3.
Slovenian: • Če slabo vidite, glejte poglavje 3.
English: • If your medicine is available in the country you are visiting.
Slovenian: • Ali je vaše zdravilo na voljo v državi, ki jo boste obiskali.
English: Age, Race, Gender and Body weight
Slovenian: Starost, rasa, spol in telesna masa
English: If you do, you may not get the correct amount of medicine.
Slovenian: Če to storite, ne boste dobili pravilnega odmerka zdravila.
English: Discuss with your doctor which pen is suitable for your needs.
Slovenian: Z zdravnikom se posvetujte, kateri peresnik je primeren za vaše potrebe.
English: ** If a different basal insulin was used:
Slovenian: ** Če je bil uporabljen drug bazalni insulin:
English: Your healthcare professional will give you this information.
Slovenian: Informacije o tem vam bo dal vaš zdravnik.
English: • You are under stress - such as emotional distress or excitement.
Slovenian: • Ste pod stresom - ste na primer v čustveni stiski ali razburjeni.
English: If a dose greater than 40 dose steps is needed, your doctor will prescribe a different strength.
Slovenian: Če potrebujete odmerek, večji od 40 odmernih korakov, vam bo zdravnik predpisal drugo jakost.
English: Take a new pen out of the refrigerator at least 1 hour before you inject.
Slovenian: Nov peresnik vzemite iz hladilnika vsaj 1 uro pred injiciranjem.
English: • You have recently had too low blood sugar (for example the day before).
Slovenian: • če ste nedavno imeli prenizek krvni sladkor (na primer prejšnji dan),
English: In such cases, you may develop severe hypoglycaemia (and even pass out) before you know what is happening.
Slovenian: V takšnih primerih se vam lahko pojavi huda hipoglikemija (in se lahko celo onesvestite), preden sploh veste, kaj se dogaja.
English: Low blood sugar means that there is not enough sugar in your blood.
Slovenian: Nizek krvni sladkor pomeni, da v krvi ni dovolj sladkorja.